Wall Street closed Thursday with tech under pressure, yields near 24-year highs and oil jumping on fresh tanker attacks near the Strait of Hormuz. Then the after-hours session rewrote the watchlist. A SpaceX spectrum deal knocked the big three wireless carriers down roughly 5% to 7%, and Medicare Advantage star ratings sent Humana up and Alignment Healthcare sharply down. Delta Air Lines reports before the bell Friday. Here are the stocks to watch tomorrow, from a $50 billion health insurer to a $3 million micro-cap, with the levels that matter for the Friday, October 9 session.
Stocks to Watch Tomorrow: Thursday’s Market Snapshot
| Metric | Thursday Close / Reading |
|---|---|
| S&P 500 | 7,765.36 (-0.47%), second straight loss |
| Nasdaq Composite | 27,193.34 (-1.25%) |
| Dow Jones Industrial Average | 51,231.64 (+0.10%) |
| Russell 2000 | 2,794.13 (+0.03%) |
| 10-Year Treasury Yield | ~5.23% (touched ~5.35% intraday) |
| VIX | ~15.4 |
| Week to Date | S&P 500 +0.6%, Nasdaq flat, Russell 2000 -1.4% |
The S&P 500 fell 0.5% for a second straight day as tech names slid, and the 10-year yield reached its highest level since 2002 on Wednesday before easing. Oil spiked as much as 5% intraday after Iran stepped up attacks on tankers near Hormuz, and growing AI caution weighed on the Nasdaq.
The after-hours shock: SpaceX agreed to buy a nationwide 800 MHz spectrum portfolio, and AT&T, T-Mobile and Verizon each fell roughly 5% to 7%. Friday’s data point is the preliminary University of Michigan sentiment reading, and Delta is the only major earnings report.
Data note: Closes are Thursday, October 8 figures. After-hours moves are as of Thursday evening and can change before the open. Where no single authoritative close was available, we say “near” or “roughly.” RSI and MACD are omitted where feeds carried stale timestamps. Support and resistance levels are analytical zones built from verified closes, after-hours prices, 52-week extremes and round numbers, not guaranteed targets.
1. Delta Air Lines (DAL) | Last Verified Close $82.97 (Oct 7) | Earnings Before the Open
DAL Reports With Jet Fuel up 40% and Street Estimates Sliding Below Guidance
Delta reports fiscal Q3 results before the opening bell Friday, with Wall Street expecting EPS of roughly $1.76 to $1.96 depending on the data provider.
| Metric | Value |
|---|---|
| Last Verified Close | $82.97 (Wed, Oct 7); Thursday trade ~$81.5–$82.1 |
| Day’s Move | ~-1% to -1.75% Thursday intraday |
| 52-Week Range | Not confirmed; stock up ~44% over 12 months |
| Market Cap | ~$54.6B |
| P/E (TTM) | ~13.7x |
| Dividend | $0.86/yr (~1.04% yield) |
| Volume vs. Average | Not final at press time |
| Analyst Consensus | Strong Buy; average target ~$103.58 (24 analysts) |
| Q3 Consensus | EPS ~$1.88 (19 analysts); revenue ~$18.8–$18.9B |
| Company Q3 Guide | Adjusted EPS $2.00–$2.50 |
| Support 1 / 2 / 3 | $81.50 / $80.00 / $77.00 |
| Resistance 1 / 2 / 3 | $82.97 / ~$85.00 / $90.00 |
Catalyst & Latest News: Estimates have slid to $1.88 from $2.11 a month ago, below the low end of Delta’s own guide. UBS forecasts $1.70 and says Q4 guidance matters more than the Q3 print, with all-in fuel near $3.15 a gallon.
Technicals: The stock sits below the roughly $85 area it held recently and is drifting lower into the print as oil rises.
Fundamentals: Management targets $6.50–$7.50 in full-year EPS and $3–$4 billion of free cash flow. The company has beaten estimates in each of the last four quarters.
Bull Case: Premium cabins and loyalty revenue, a four-quarter beat streak and a target roughly 25% above the price. Bear Case: Fuel costs and refinery outages, cut estimates, and a Zacks rank that signals lower odds of a beat.
What to Watch:
- Q4 revenue growth guidance (UBS flags 20%+ as a positive trigger)
- Fuel cost commentary and the full-year EPS range
- Whether $81.50 holds at the open
Forecast: A beat with Q4 guidance above 20% growth could lift DAL through $85. A fuel-driven guide-down puts $80, then $77, in play.
Why This Matters: Delta is the opening read on how much of an oil shock the consumer and the airlines can absorb.
2. Humana (HUM) | After-Hours $436.50 (+12.8%) | Medicare Stars Rebound
A 4-Star Contract Upgrade Sends the Insurer to a Fresh High After the Bell
Humana surged as much as 13% after hours when CMS upgraded its largest Medicare Advantage contract to 4 stars.
| Metric | Value |
|---|---|
| Last Close | ~$387 (derived from the after-hours quote) |
| After-Hours | $436.50 (+12.8%) |
| 52-Week High | $409.80 (September) before this move |
| Market Cap | ~$46B (estimated) |
| YTD | ~+46% at the close; up 54% as of late September |
| Volume vs. Average | Heavy after-hours dollar volume; final tally not confirmed |
| Analyst View | Barclays upgraded to Overweight in September |
| Key Stat | Largest contract back to 4 stars from 3.5 |
| Support 1 / 2 / 3 | $409.80 / ~$387 / $360 |
| Resistance 1 / 2 / 3 | $436.50 / $450 / $460 |
Catalyst & Latest News: After the October 2024 ratings, Humana’s share of members in 4-star-plus plans fell from 94% to 25%. This year’s upgrade restores bonus eligibility for 2028.
Technicals: The stock gaps above its prior 52-week high of $409.80, so that level becomes first support if the gain holds.
Fundamentals: Barclays moved to Overweight on September 25, lifting shares about 8% that day. The stock has had 18 moves above 5% in a year.
Bull Case: Bonus payments return in 2028, and the stock breaks out to new highs. Bear Case: A 13% after-hours spike is vulnerable to a morning fade, and the ratings do not change this year’s results.
What to Watch:
- Whether $409.80 holds as support
- Analyst target hikes at the open
- Read-through to other Medicare Advantage names
Forecast: Holding above $409.80 keeps the breakout alive toward $450. A slide back through $387 would erase the gap.
Why This Matters: Star ratings drive billions in annual bonus payments, and Humana just got a large part of that back.
3. Alignment Healthcare (ALHC) | Close $8.71 (+1.9%) | After-Hours About -20% | Star Ratings Blow
The Insurer’s California Contract Slips to 3.5 Stars, Pushing Shares Toward Record Lows
Alignment’s key California HMO contract fell to 3.5 stars from 4.0, affecting about 75% of its membership, and the stock fell between 20% and 23% after hours.
| Metric | Value |
|---|---|
| Last Close | $8.71 (+1.87%) |
| After-Hours | ~$6.98 (about -20%); reports range -20% to -23% |
| 52-Week Range | $7.37 – $25.12 (new low in after-hours) |
| Market Cap | ~$1.77B at the close |
| P/E (TTM) | ~45.8x |
| Dividend | None |
| Volume vs. Average | Average ~10.8M shares; after-hours volume heavy |
| YTD | About -49% as of mid-September, before this drop |
| Analyst View | ~86% Buy; targets cited ~$19–$22 |
| Support 1 / 2 / 3 | $6.98 / $6.50 / $6.00 |
| Resistance 1 / 2 / 3 | $7.37 / $8.71 / $10.00 |
Catalyst & Latest News: Alignment’s own release highlights six of seven contracts at 4 stars or higher, but the downgraded contract covers most members. Management declined to discuss stars on the September call, and the stock was then on track for its worst day ever.
Technicals: A break below the $7.37 52-week low opens price discovery, and the old low is now resistance.
Fundamentals: Quality bonuses for 2028 are at risk on the affected contract. Analysts had trimmed targets before the news.
Bull Case: Targets near $19–$22 imply large upside, and six contracts held strong ratings. Bear Case: Three-quarters of membership sits under the downgrade, and the stock has no support below $7.
What to Watch:
- Analyst downgrades or target cuts at the open
- Any management comment on appeal or bonus impact
- A hold or break of $6.98
Forecast: Bounces should struggle at $7.37. A reclaim of $8.71 would be needed to heal the chart; a break of $6.50 points to $6.
Why This Matters: ALHC shows how one star-rating cut can erase a year of valuation in a night.
4. Clover Health (CLOV) | Close ~$4.1 | After-Hours About +11% | A 5-Star PPO
Clover Earns a 5-Star PPO Rating While a Rival Stumbles
Clover’s PPO Medicare Advantage plans earned 5 stars and its HMO plan 4.5 stars for 2027, lifting shares about 11% after hours.
| Metric | Value |
|---|---|
| Last Close | ~$4.1 (estimated from the after-hours quote) |
| After-Hours | ~$4.5–$4.6 (about +11%) |
| 52-Week Range | Not confirmed at press time |
| Market Cap | ~$2.4B |
| P/E / Dividend | Not meaningful / None |
| Volume vs. Average | Not final at press time |
| Valuation Marker | GuruFocus fair value ~$4.03, shares modestly above it |
| Key Stat | PPO 5.0 stars, HMO 4.5 stars |
| Support 1 / 2 / 3 | $4.13 / $3.90 / $3.50 |
| Resistance 1 / 2 / 3 | $4.58 / $5.00 / $5.50 |
Catalyst & Latest News: A 5-star rating lets Clover’s PPO plans enroll members year-round, and the rating affects payment year 2028.
Technicals: The after-hours pop puts the stock near a $4.58 area that now acts as first resistance.
Fundamentals: GuruFocus rates the stock modestly overvalued on its own fair-value model, with a GF Score of 74.
Bull Case: Year-round enrollment is a membership engine, and rival Alignment’s stumble may shift share. Bear Case: An 11% after-hours gain can fade, and the valuation already sits above one fair-value estimate.
What to Watch:
- Whether $4.58 converts to support
- Analyst target changes
- Enrollment commentary into open season
Forecast: A close above $4.58 points to $5. Failing to hold the $4.13 gap level would hand the gain back.
Why This Matters: Clover is the small-cap winner of the same ratings release that cut Alignment, a clean sector read.
5. Veea (VEEA) | Close ~$3.87 | After-Hours +49% to $5.77 | Nasdaq Compliance Restored
A Boardroom Fix Triggers a 49% After-Hours Jump in a Stock That Has Already Whipsawed 5x
Veea said it regained full Nasdaq compliance after fixing its remaining governance gaps, and shares leapt about 49% after the bell.
| Metric | Value |
|---|---|
| Last Close | ~$3.87 (derived from the after-hours quote) |
| After-Hours | $5.77 (+49.1%) |
| Recent Range | $1.60 (Sept 14) to $8.88 (Sept 17 high) |
| Market Cap | Micro-cap; share-count data inconsistent |
| P/E / Dividend | Negative (EPS about -$2.80) / None |
| Q2 Revenue | $176.2K (+141.6% YoY) |
| Volume vs. Average | Extremely high on prior spikes; Thursday final not confirmed |
| Analyst View | None confirmed |
| Support 1 / 2 / 3 | $3.87 / ~$3.40 / $2.00 |
| Resistance 1 / 2 / 3 | $5.77 / $7.00 / $8.88 |
Catalyst & Latest News: Veea doubled in September on a $750 million NovaGen merger term sheet and a $10 million investment from GeoNova. A Trollee deployment deal then triggered another spike.
Technicals: After the September blow-off, the stock churned between roughly $2 and $4.50, and closes of $3.33–$3.47 formed a base before tonight’s jump.
Fundamentals: Governance gaps arose after an independent director died, and a new board member filled the committee seat. GuruFocus’s financial-health score is a low 4 out of 100.
Bull Case: A pending merger, restored listing status and heavy retail interest. Bear Case: Revenue is tiny, losses are large, a definitive merger agreement is not signed, and the stock has reversed sharply before.
What to Watch:
- Whether the open holds above $5
- Any definitive NovaGen agreement
- Dilution or financing announcements
Forecast: A hold above $5.77 targets $7. Fading back below $3.87 would erase the gain.
Why This Matters: VEEA is a textbook headline-driven small cap, and Friday will test whether a governance fix has real staying power.
6. XORTX Therapeutics (XRTX) | Close $1.85 (+6.0%) | After-Hours +24.6% to $2.31
A $3 Million Gout Biotech Lights Up on a Health Canada Filing Plan
XORTX outlined its planned Health Canada trial application for its XRx-026 gout program, and shares rose after hours.
| Metric | Value |
|---|---|
| Last Close | $1.85 (+6.02%; prior close $1.745) |
| After-Hours | $2.305 (+24.6%) |
| Day’s Range | $1.72 – $1.90 |
| 52-Week Range | $1.59 – $7.05 |
| Market Cap | ~$3.4M (about 1.8M shares) |
| P/E / Dividend | Negative (EPS -$2.83) / None |
| Volume vs. Average | ~10.2M vs. ~230K average |
| Analyst Coverage | None |
| Next Earnings | Mid-November |
| Support 1 / 2 / 3 | $1.75 / $1.59 / $1.50 |
| Resistance 1 / 2 / 3 | $2.31 / $2.50 / $3.00 |
Catalyst & Latest News: The plan supports a two-part XRX-OXY-102 study, and management cited rising interest from potential commercialization partners.
Technicals: Volume was roughly 45 times the daily average, and the stock closed just above its $1.59 52-week low.
Fundamentals: XRx-026 is a Phase III gout program using XORLO, an oxypurinol formulation. The company has a market value of about $3 million.
Bull Case: Partnering interest and an accelerated pivotal path. Bear Case: Extreme dilution risk, no analyst coverage and liquidity that can vanish. Per Stock Analysis, market cap fell about 29% over the past year.
What to Watch:
- A hold above $1.85 at the open
- A partnership announcement
- Any financing announcement
Forecast: Holding $2.31 opens $2.50. A fade under $1.75 returns the stock to its $1.59 low.
Why This Matters: XRTX shows how a procedural filing can move a micro-cap 25% when almost nothing else trades.
7. Park Aerospace (PKE) | Close $29.66 (+1.4%) | Earnings Beat, Mixed After Hours
Missile Demand Lifts a Quiet Composites Maker, but GE Engine Guidance Slips
Park Aerospace reported fiscal Q2 EPS of $0.21 on sales of $20.8 million, against estimates near $0.16 and $20.0 million.
| Metric | Value |
|---|---|
| Last Close | $29.66 (+1.37%; prior close $29.26) |
| After-Hours | ~+3.5% to $30.70, later closer to -1% |
| 52-Week Range | $18.25 – $39.86 |
| Market Cap | ~$654M |
| P/E (TTM) | ~45x (estimated) |
| Dividend | ~$0.50/yr (~1.7% yield) |
| Volume vs. Average | Average ~312K shares; Thursday final not confirmed |
| Analyst View | Two analysts, Buy |
| Q2 Results | Sales $20.8M; adjusted EBITDA $5.3M; gross margin 34.3% |
| Support 1 / 2 / 3 | $29.26 / $28.00 / $25.00 |
| Resistance 1 / 2 / 3 | $30.70 / ~$33.90 / $39.86 |
Catalyst & Latest News: Adjusted EBITDA topped management’s own range, and Q3 sales are guided to $21–$22.5 million. The GE Aerospace engine program forecast was cut to $32–$35 million.
Technicals: The stock sits about 25% below its 52-week high, and the after-hours reaction flipped from a gain to a small loss.
Fundamentals: Net earnings rose to $4.5M from $2.4M a year ago, and the effective tax rate was 18.6% versus 1% in Q1.
Bull Case: Missile demand, margin above 34% and an earnings beat of about 31%. Bear Case: GE guidance cut, a P/E in the mid-40s and a thinly covered stock.
What to Watch:
- Follow-through above $30.70
- Analyst target changes
- Commentary on the missile ramp
Forecast: A close above $30.70 opens the $33–$34 zone. Losing $29.26 points to $28.
Why This Matters: Park is a small aerospace supplier where defense demand is offsetting a softer engine program.
8. Tilray Brands (TLRY) | Near $3.7 (About -4%) | Revenue Miss, Record Beverage Sales
Record Revenue Meets a Wider Loss, and the Stock Sits Near a 52-Week Low
Tilray posted record Q1 revenue of $257.1 million, up 23%, but the figure missed estimates by roughly $10 million.
| Metric | Value |
|---|---|
| Last Price | Near $3.7 (market cap ~$549M on ~145M shares) |
| Day’s Move | About -4% after the report |
| 52-Week Range | $3.375 – $23.20 |
| Market Cap | ~$549M |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Not final at press time |
| 1-Year | About -78% |
| Q1 Results | Revenue $257.1M; gross margin 30%; adjusted EBITDA $9.2M |
| FY27 Guide | Adjusted EBITDA $68–$75M (reaffirmed) |
| Support 1 / 2 / 3 | $3.375 / $3.00 / $2.75 |
| Resistance 1 / 2 / 3 | ~$3.95 / $4.50 / $5.00 |
Catalyst & Latest News: Shares slipped premarket as cannabis revenue fell 13% to $56.1 million, while beverage revenue rose 82% to $101.5 million on BrewDog.
Technicals: The stock trades just above the bottom of its 52-week range with a beta near 1.9, so a break of $3.375 would mark a new low.
Fundamentals: The company cut debt by $42 million this fiscal year and ended the quarter net cash positive, per its 8-K. The GAAP loss was $0.32 per share versus $0.16–$0.19 expected.
Bull Case: Record gross profit, EMEA growth above 70% and a reaffirmed EBITDA guide. Bear Case: Shrinking domestic cannabis, a wider net loss and seasonality that pushes profits to the second half.
What to Watch:
- A hold of $3.375
- Analyst target cuts
- Beverage margin trends
Forecast: Holding $3.375 keeps a base intact, with $3.95 first resistance. A break lower points to $3.
Why This Matters: Tilray shows how growth and profitability can diverge, and the market is punishing the gap.
9. Byrna Technologies (BYRN) | Roughly $3.7 (About -9.6%) | Revenue Falls 46%
Less-Lethal Maker Posts a 46% Revenue Drop, and a Tariff Refund Props Up Margins
Byrna reported fiscal Q3 revenue of $15.3 million versus $28.2 million a year ago, and shares fell about 9.6%.
| Metric | Value |
|---|---|
| Last Price | Roughly $3.7 (prior close near $4.1) |
| Day’s Move | About -9.6% |
| 52-Week Range | Not confirmed at press time |
| Market Cap | ~$85–$95M (about 23M shares) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | Not final at press time |
| Q3 Results | Revenue $15.3M (est. ~$16.2–$16.6M); loss $0.13 per share |
| Cash | $9.4M versus $15.5M at fiscal year-end |
| Support 1 / 2 / 3 | $3.50 / $3.00 / $2.75 |
| Resistance 1 / 2 / 3 | $4.05 / $4.50 / $5.00 |
Catalyst & Latest News: The decline reflects weaker e-commerce sales and slower dealer reorders, and the release carried no formal guidance.
Technicals: The stock had climbed about 13% in the prior month, so the report reversed a run-up.
Fundamentals: Gross margin was 79%, or about 65% excluding a one-time $2.3 million tariff refund. Adjusted EBITDA was -$1.4 million, and the loss per share narrowed versus estimates.
Bull Case: Management expects sequential improvement and new commercial programs. Bear Case: Revenue is nearly cut in half, cash is down about 39% since fiscal year-end, and spending is rising.
What to Watch:
- Dealer reorder commentary
- A hold of $3.50
- Cash runway
Forecast: A close back above $4.05 would repair the damage. Below $3.50, $3 is next.
Why This Matters: Byrna’s slide is a warning on consumer-defense demand after a restocking cycle.
10. Chipotle Mexican Grill (CMG) | Close $32.68 (+6.2%) | Starbucks Takeover Report
A Reported Starbucks Bid Lifts the Burrito Chain 6% as Starbucks Falls Below $90
Chipotle jumped as much as 8.6% after the Financial Times reported that Starbucks explored a takeover, and it closed up 6.2%.
| Metric | Value |
|---|---|
| Last Close | $32.68 (+$1.91, +6.21%) |
| Prior Close | ~$30.77 |
| Intraday High | ~$33.42 (+8.6%) |
| 52-Week Range | $28.04 – $42.82 (as of early October) |
| Market Cap | ~$39–$43B depending on source |
| P/E / Dividend | Not confirmed / None |
| Volume vs. Average | Not final at press time |
| Starbucks | ~$89.76 (-4.1% mid-afternoon); 52-week range $77.99–$110.51 |
| Support 1 / 2 / 3 | $30.77 / $30.00 / $28.04 |
| Resistance 1 / 2 / 3 | $33.42 / $35.00 / $36.00 |
Catalyst & Latest News: The deal would reunite CEO Brian Niccol with the chain he previously led, but the FT cautioned a transaction this size may never happen. Starbucks options traded heavily on the report.
Technicals: The stock reclaimed $32 after trading near $30–$31 earlier in the week, and gave back some of its intraday gain.
Fundamentals: The combined company would have roughly $50 billion in annual sales. A restaurant-sector slump has weighed on both shares since late August.
Bull Case: A takeover premium, a depressed valuation and a strategic buyer. Bear Case: No offer exists, a deal faces antitrust and financing hurdles, and the pop can fully reverse.
What to Watch:
- Any Starbucks or Chipotle statement
- A hold of $32
- Starbucks’ reaction at the open
Forecast: Holding $32.68 keeps $33.42 in view. A denial would send CMG back toward $30.77.
Why This Matters: A single press report added roughly $2.5 billion to Chipotle’s value, and deal speculation can move fast.
Stocks to Watch Tomorrow: Sector Sentiment Snapshot and Forecast
Healthcare is the busiest corner, with Humana and Clover up and Alignment crushed on one ratings release. Telecom is under a new cloud as SpaceX moves into spectrum, and airlines face an oil test with Delta first up. Small caps are speculative: Veea and XORTX are moving on procedural news in thin markets. The forecast for Friday is headline-driven, with Delta’s guide, the Michigan sentiment reading and Hormuz oil headlines the likely market movers.
At a Glance: Stocks to Watch Tomorrow (Oct 9, 2026)
| # | Ticker | Last Close / Price | Move | Catalyst | Key Level |
|---|---|---|---|---|---|
| 1 | DAL | $82.97 (Oct 7) | ~-1% Thu | Q3 earnings, pre-market | $81.50 / $85 |
| 2 | HUM | ~$387 | +12.8% AH | Medicare star ratings | $409.80 / $436.50 |
| 3 | ALHC | $8.71 | ~-20% AH | Star-rating downgrade | $6.98 / $7.37 |
| 4 | CLOV | ~$4.1 | ~+11% AH | 5-star PPO rating | $4.13 / $4.58 |
| 5 | VEEA | ~$3.87 | +49% AH | Nasdaq compliance | $3.87 / $5.77 |
| 6 | XRTX | $1.85 | +24.6% AH | Health Canada plan | $1.75 / $2.31 |
| 7 | PKE | $29.66 | +1.4% | Q2 earnings beat | $29.26 / $30.70 |
| 8 | TLRY | ~$3.7 | ~-4% | Q1 revenue miss | $3.375 / $3.95 |
| 9 | BYRN | ~$3.7 | ~-9.6% | Q3 revenue -46% | $3.50 / $4.05 |
| 10 | CMG | $32.68 | +6.2% | Starbucks takeover report | $30.77 / $33.42 |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap, micro-cap, clinical-stage biotech and other high-volatility stocks carry elevated risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change, particularly after-hours quotes. Some prices are approximate or derived from after-hours moves where exact closing data was not available. Support and resistance levels are analytical reference zones, not guaranteed price targets. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
